Bioanalytical Support in the Development of Biologics
Case studies on ultra sensitive bioanalysis of biologics with challenging molecular characteristics and the need for broad assay range are discussed. more
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Fig.1 In a given population, the prognostic biomarker sorts the individuals with a likely course of a disease if untreated (blue and green). Predictive biomarkers identify subpopulations of patients who are likely to respond to a given therapy (blue). The drug dosage for responsive individuals is optimized by analysis of pharmacodynamic biomarkers.
Summery
Biomarkers are currently changing the way we diagnose and treat diseases. Today pharmacodynamic biomarkers are widely used in the industry elaborating optimal dosing of new drugs and predictive biomarkers have an enormous potential for companion diagnostics (1).
Background
Challenge 1: How to study base levels?
While elevated cytokine marker concentrations in patients are well documented, limited data are available for endogenous baseline concentrations for the majority of biomarkers (2). In clinically relevant study set ups several cytokine markers specific for inflammatory diseases were quantified in human biological matrix. The aim was to determine baseline cytokine concentrations in individual healthy human individuals.
Strategic consideration for biomarker quantification:
Results 1
Low fg/ml concentration limits of TNF-alpha in human serum was shown with Imperacer® in comparison to other standard ligand binding technology (4).
Results 2
The ultra sensitive Imperacer® technology, quantifies fg/ml concentrations of several clinically relevant cytokines in human serum matrix. This low level quantification enables the detection of endogenous baseline concentrations as well as biomarker surveillance throughout several phases of a clinical study (5).
Cytokine | LOD Imperacer® |
Matrix |
IL-2 | 0,1 pg/ml | Serum |
IL-6 | 0,1 pg/ml | Serum |
IL-8 | 0,1 pg/ml | Serum |
IL-11 | 0,8 pg/ml | Serum |
IL-12 | 0,05 pg/ml | Serum |
IL-17 | 0,02 pg/ml | Tissue culture |
IL-23 | 0,17 pg/ml | Serum |
INF-gamma | 0,3 pg/ml | Cell lysate |
TNF-alpha | 0,01 pg/ml | Serum |
Tab.1 Ultra low quantification of several predictive and pharmacodynamic biomarkers (5)
Fig.3 Response in muscle fiber diameter increase after treatment in individual patients (6).
Challenge 2: How to study pharmacodynamic profiles?
Blocking of the myostatin (MSTN) signaling pathway by inhibitors, e.g. MSTN neutralizing antibodies, result in drastic increase of skeletal muscle mass. Clinical studies focusing on diseases interfering muscle growth, e.g. muscle dystrophy, mostly generate data by muscle biopsies to analyze increase or decrease of muscle mass and muscle fiber diameter after treatment (6). A less invasive strategy is to exploit molecular biomarkers for muscle growth e.g. myostatin propeptide (MYO-P) or follistatin to generate reliable clinical data on molecular basis from biomarker concentration in blood (3).
Fig.4A Broad dynamic range and sub pg/ml levels of MSTN inhibitors in blood serum compared to standard ELISA(3).
Results 3
Based on clinical studies on MSTN inhibitors like neutralizing antibodies, further analysis has been reported by detection MSTN inhibitor concentrations in serum. MYO-P as well as follistatin is here detected in pg/ml concentration levels in blood serum (3).
Fig.4B Broad dynamic range and sub pg/ml levels of MSTN inhibitors in blood serum compared to standard ELISA(3).
Conclusion:
Imperacer® as prime technology in clinical studies enabled specific biomarker quantification in sub pg/ml detection limits and broad dynamic range.
Literature:
Bioanalytical Support in the Development of Biologics
Case studies on ultra sensitive bioanalysis of biologics with challenging molecular characteristics and the need for broad assay range are discussed. more
Immunoassay support for clinical PK assessment where ELISA fails
Case studies on ultra sensitive bioanalysis of biologics with challenging molecular characteristics, like toxins or fusion-proteins are discussed more
Ultra-sensitive Biomarker Quantification in Microsampling Support
Looking for Biomarker quantification in microsampling support? Imperacer® enables target detection in low pg/ml range with lowest sample consumption. more
Mymetics Corporation announced that its subsidiary Mymetics BV in the Netherlands is leading a consortium that has been selected to receive project grants with a total value of €8.4 million. A total of €5.3 million is funded as part of Horizon 2020, the European Union research and innovati ... more
Drug Development Technology: Frost & Sullivan Award goes to Imperacer
The 2008 European Immunoassay Frost & Sullivan Excellence in Technology Award has been awarded to Chimera Biotec. Chimera Biotec is recognized for its pioneering Imperacer® ultra-sensitive immunoassay system, which has a 1000-fold better sensitivity compared to ELISA (Enzyme-linked Immunoso ... more
Chimera Biotec invites scientists to the III. Immunolympics 2008
For the third time Chimera Biotec supports the scientific community with a contest on ultra-sensitive immunoassays, the III. Immunolympics are open. The contest seeks to find potential solutions to today's scientific challenges using ultra-sensitive immunoassays. It's the third time that ... more
Chimera Biotec is dedicated to the development of ultra-sensitive, customer-specific immunoassays for protein analysis based on their proprietary Imperacer® technology. Furthermore Chimera offers services and products for a broad range of applications. more
breadcrumb_whitepaper